-
公开(公告)号:US20080045529A1
公开(公告)日:2008-02-21
申请号:US10577908
申请日:2004-10-14
申请人: Hans-Michael Eggenweiler , Alfred Jonczyk , Gerhard Barnickel , Wilfried Rautenberg , Helga Drosdat , Arne Sutter
发明人: Hans-Michael Eggenweiler , Alfred Jonczyk , Gerhard Barnickel , Wilfried Rautenberg , Helga Drosdat , Arne Sutter
IPC分类号: A61K31/5377 , A61K31/496 , A61K31/497 , A61P29/00 , A61P37/00 , C07D295/00 , C07D239/20 , A61P35/00 , A61P27/02 , A61K31/519
CPC分类号: C07D495/04 , A61K31/505
摘要: The invention relates to compounds of formula (I), wherein R1, R2, R3, R4, X and n have the meanings cited in claim (1). Said compounds are inhibitors of tyrosinkinases, especially TIE-2, and Raf-Kinases and can be used, for example, in the treatment of tumours.
摘要翻译: 本发明涉及式(I)化合物,其中R 1,R 2,R 3,R 4, >,X和n具有权利要求(1)中引用的含义。 所述化合物是酪氨酸酶,特别是TIE-2和Raf-激酶的抑制剂,可以用于例如肿瘤的治疗。
-
2.
公开(公告)号:US20050070529A1
公开(公告)日:2005-03-31
申请号:US10467793
申请日:2002-01-15
申请人: Arne Sutter , Thomas Ehring , Thomas Welge , Klause Minck , Claudia Wilm , Michael Gassen , Hans-Michael Eggenweiler , Michael Wolf , Pierre Schelling , Norbert Beier , Joachim Leibrock
发明人: Arne Sutter , Thomas Ehring , Thomas Welge , Klause Minck , Claudia Wilm , Michael Gassen , Hans-Michael Eggenweiler , Michael Wolf , Pierre Schelling , Norbert Beier , Joachim Leibrock
IPC分类号: A61K31/50 , A61K31/501 , A61K31/535 , A61K31/5395 , A61K31/54 , A61K31/549 , A61P9/00 , A61P29/00 , A61P37/02
CPC分类号: A61K31/50 , A61K31/5395 , A61K31/549
摘要: The invention relates to the use of type 4 phosphodiesterase inhibitors to treat myocardial diseases.
摘要翻译: 本发明涉及使用4型磷酸二酯酶抑制剂来治疗心肌疾病。
-
公开(公告)号:US08791129B2
公开(公告)日:2014-07-29
申请号:US13819109
申请日:2011-08-31
IPC分类号: A01N43/54 , A61K31/517 , C07D239/72 , C07D401/00
CPC分类号: A61K31/517 , A61K31/675 , A61K45/06 , C07D401/14 , C07D403/06 , C07D403/14 , C07D405/14 , C07F9/65583
摘要: Novel quinazolinamide derivatives of the formula (I), in which R1-R43 and X have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
摘要翻译: 式(I)的新颖的喹唑啉酰胺衍生物,其中R1-R43和X具有权利要求1所述的含义,是HSP90抑制剂,可用于制备用于治疗其中抑制,调节和 /或HSP90调节起作用。
-
公开(公告)号:US08618285B2
公开(公告)日:2013-12-31
申请号:US11816465
申请日:2006-01-25
IPC分类号: A61K31/4196 , C07D249/12 , C07D401/12 , C07D503/12
CPC分类号: C07D249/12
摘要: Novel triazole derivatives of the formula (I), in which R1-R6, and Y have the meanings indicated in claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
摘要翻译: 式(I)的新型三唑衍生物,其中R 1 -R 6和Y具有权利要求1所述的含义,是HSP90抑制剂,可用于制备用于治疗其中抑制,调节 和/或调节HSP90起作用。
-
公开(公告)号:US20130178443A1
公开(公告)日:2013-07-11
申请号:US13819109
申请日:2011-08-31
IPC分类号: A61K31/517 , C07D401/14 , A61K45/06 , C07D405/14 , C07F9/6558 , A61K31/675 , C07D403/06 , C07D403/14
CPC分类号: A61K31/517 , A61K31/675 , A61K45/06 , C07D401/14 , C07D403/06 , C07D403/14 , C07D405/14 , C07F9/65583
摘要: Novel quinazolinamide derivatives of the formula (I), in which R1-R43 and X have the meanings indicated in claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
摘要翻译: 式(I)的新型喹唑啉酰胺衍生物,其中R1-R43和X具有权利要求1所述的含义,是HSP90抑制剂,可用于制备用于治疗其中抑制,调节和 /或HSP90调节起作用。
-
6.
公开(公告)号:US20090197882A1
公开(公告)日:2009-08-06
申请号:US12307030
申请日:2007-06-18
IPC分类号: A61K31/416 , A61K31/5355 , A61K31/5377 , A61K31/454 , A61K31/496 , A61K31/4184 , C07D413/12 , C07D401/12 , C07D231/56 , A61P35/00 , C07D403/12 , C07D405/12
CPC分类号: C07D403/12 , C07D231/56 , C07D405/12
摘要: Novel indazole derivatives of the formula (I), in which R1-R3 have the meanings indicated in Claim (1), are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
摘要翻译: 式(I)的新型吲唑衍生物,其中R1-R3具有权利要求(1)所示的含义,是HSP90抑制剂,可用于制备用于治疗其中抑制,调节和 /或HSP90调节起作用。
-
公开(公告)号:US07491742B2
公开(公告)日:2009-02-17
申请号:US10750878
申请日:2004-01-05
IPC分类号: A61K31/415
CPC分类号: C07D491/04 , C07D495/04
摘要: Imidazole derivatives of the formula I in which R1 is H, A, benzyl, indan-5-yl, 1,2,3,4-tetrahydronaphthalen-5-yl, dibenzothien-2-yl, or phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, A-CO—NH, benzyloxy, alkoxy, COOH or COOA, R2 is H or A, X is O or S, Hal is F, Cl, Br or I, A is alkyl with 1 to 6 C atoms, and the physiologically acceptable salts and/or solvates thereof as phosphodiesterase VII inhibitors and the use thereof for producing a pharmaceutical.
摘要翻译: 式I的咪唑衍生物,其中R 1是H,A,苄基,茚满-5-基,1,2,3,4-四氢萘-5-基,二苯并噻吩-2-基或未取代或单 - ,Hal,A,A-CO-NH,苄氧基,烷氧基,COOH或COOA二取代或三取代,R 2为H或A,X为O或S,Hal为F,Cl,Br或I, 1至6个C原子,以及其作为磷酸二酯酶VII抑制剂的生理学上可接受的盐和/或溶剂合物及其用于制备药物的用途。
-
公开(公告)号:US20050059686A1
公开(公告)日:2005-03-17
申请号:US10500040
申请日:2002-11-08
IPC分类号: C12N9/99 , A61K31/519 , A61K45/00 , A61P1/04 , A61P1/12 , A61P1/16 , A61P3/10 , A61P5/00 , A61P5/02 , A61P5/38 , A61P7/00 , A61P7/02 , A61P7/04 , A61P7/06 , A61P7/08 , A61P9/04 , A61P9/08 , A61P9/10 , A61P9/12 , A61P9/14 , A61P11/00 , A61P11/02 , A61P11/04 , A61P11/06 , A61P11/08 , A61P11/10 , A61P11/16 , A61P13/02 , A61P13/08 , A61P13/12 , A61P15/00 , A61P17/00 , A61P17/04 , A61P17/06 , A61P19/02 , A61P19/06 , A61P19/08 , A61P19/10 , A61P21/04 , A61P25/00 , A61P25/04 , A61P25/14 , A61P25/16 , A61P25/24 , A61P25/28 , A61P25/30 , A61P27/02 , A61P27/14 , A61P29/00 , A61P31/00 , A61P31/04 , A61P31/10 , A61P31/14 , A61P31/16 , A61P31/18 , A61P31/20 , A61P31/22 , A61P33/06 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/00 , A61P37/06 , A61P37/08 , A61P41/00 , A61P43/00 , C07D487/04 , C07D487/02
CPC分类号: C07D487/04
摘要: Pyrrolopyrimidine derivatives of the formula I in which R3, R4, R5, R6 and X are as defined in claim 1, act as phosphodiesterase VII inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
摘要翻译: 其中R 3,R 4,R 5,R 6和X如权利要求1所定义的式I的吡咯并嘧啶衍生物作为磷酸二酯酶VII抑制剂,可用于治疗骨质疏松症 ,肿瘤,恶病质,动脉粥样硬化,类风湿性关节炎,多发性硬化,糖尿病,炎性过程,过敏,哮喘,自身免疫疾病,心肌疾病和艾滋病。
-
公开(公告)号:US06780867B2
公开(公告)日:2004-08-24
申请号:US10362993
申请日:2003-03-03
IPC分类号: A61K31519
CPC分类号: C07D495/04
摘要: Thienopyrimidines of the formula (I) and their physiologically acceptable salts, in which R1, R2 and X are as defined in claim 1, exhibit phosphodiesterase V inhibition and can be employed for the treatment of illnesses of the cardiovascular system and for the treatment and/or therapy of impotence.
摘要翻译: 式(I)的噻吩并嘧啶及其生理上可接受的盐,其中R 1,R 2和X如权利要求1中所定义,表示磷酸二酯酶V抑制,可用于治疗心血管系统疾病 并用于治疗和/或治疗阳。。
-
公开(公告)号:US08969335B2
公开(公告)日:2015-03-03
申请号:US14342911
申请日:2012-08-13
IPC分类号: A61K31/506 , A61K31/4523 , A61K31/4427 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/10 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/497 , A61K31/501 , A61K31/5377 , A61K45/06 , C07D491/107
CPC分类号: C07D401/12 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/10 , C07D491/107
摘要: Compounds of the formula I, in which R1, R2, X and Y have the meanings indicated in Claim 1, are inhibitors of TBK1 and IKKε and can be employed, inter alia, for the treatment of cancer and inflammatory diseases.
摘要翻译: 其中R1,R2,X和Y具有权利要求1所述含义的式I化合物是TBK1和IKK的抑制剂, 并且可以用于治疗癌症和炎性疾病。
-
-
-
-
-
-
-
-
-